Clinical Trials | October 13, 2025
Moderna’s mRNA-4359 shows promising early results in resistant Melanoma at ESMO 2025
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
The new data highlight the potential of AstraZeneca’s innovative therapies to improve outcomes across multiple cancer types
ExellenS applies optimized facility designs, equipment, and processes across all sites to ensure equivalency and speed
AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing
Merck will showcase results in innovative solutions in HIV treatment and prevention
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults
PeptiGlow features premium-grade hydrolyzed collagen peptides that support skin elasticity and hydration
The Court dismissed Swiss drugmaker Roche’s plea for interim injunction
Subscribe To Our Newsletter & Stay Updated
